Multiple Sclerosis Competitive Landscape 2026: 75+ Companies, 80+ Pipeline Therapies, 15+ Key FDA & Clinical Milestones Driving the Future of Multiple Sclerosis Treatment, analyses DelveInsight

Multiple Sclerosis Competitive Landscape

According to DelveInsight’s evaluation, the global Multiple Sclerosis (MS) pipeline includes more than 75 prominent companies actively engaged in the development of over 80 treatment candidates. The assessment covers detailed insights into clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and recent developmental advancements.

DelveInsight’s Multiple Sclerosis Pipeline Insight 2026 report delivers extensive worldwide analysis of Multiple Sclerosis drug candidates across various stages of clinical development. It highlights the efforts of leading pharmaceutical and biotechnology companies focused on strengthening the pipeline landscape and unlocking future growth opportunities within the Multiple Sclerosis market.

Key Highlights from the Multiple Sclerosis Pipeline Report

• DelveInsight’s Multiple Sclerosis competitive landscape analysis outlines a dynamic and expanding ecosystem, with 75+ companies collectively advancing more than 80 investigational therapies targeting multiple sclerosis.
• Major industry participants, including Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen, Nucleome Therapeutics, Medsenic, TeraImmun, Autobahn Therapeutics, Guangzhou Lupeng Pharmaceutical, GlaxoSmithKline, ImCyse, Novartis, Biocad, Apimeds, Genentech, Merck, AB Science, Apurano Pharmaceuticals, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., and Ever Supreme Bio Technology Co., Ltd., among others, are actively investigating innovative MS therapies aimed at enhancing the current treatment paradigm.
• Several promising drug candidates—including SAR 441344, IMU-838, Orelabrutinib, Foralumab, BIIB091, JPH 034, CC-97540, PB018, autoimmune disorder vaccines, NVG300, NT-0002, Arscimed, TI-235, LL-341070, LP-168, GSK 3888130B, and IMCY-0141—are progressing through various phases of clinical trials, demonstrating significant potential to transform the future MS therapeutic landscape.

Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Competitive Report

Multiple Sclerosis Overview

Multiple Sclerosis (MS) is a chronic, immune-mediated neurological disorder in which the body’s immune system mistakenly attacks the protective myelin sheath covering nerve fibers in the central nervous system. This damage disrupts communication between the brain and the rest of the body, leading to symptoms such as fatigue, vision problems, muscle weakness, numbness, balance issues, and cognitive impairment. MS typically follows relapsing-remitting or progressive disease courses. Although the exact cause remains unknown, genetic and environmental factors contribute to its development. While there is no cure, disease-modifying therapies and symptomatic treatments help manage progression and improve patients’ quality of life.

Treatment includes disease-modifying therapies (DMTs) to regulate the immune response and symptomatic therapies to manage clinical effects. Since 2013, 12 DMTs have been approved by the FDA/EMA, including dimethyl fumarate (TECFIDERA), alemtuzumab (LEMTRADA), pegylated interferon-β (PLEGRIDY), and glatiramer acetate (COPAXONE).

Key Developments in the Multiple Sclerosis Treatment Space

• On February 7, 2026, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK) inhibitor fenebrutinib met its primary endpoint of non-inferiority compared to Ocrevus® (ocrelizumab) in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS). Fenebrutinib showed a 12% reduction in the risk of disability progression compared to Ocrevus, the only approved medicine for PPMS, as measured by the time to onset of 12-week composite confirmed disability progression (cCDP12) (hazard ratio [HR] 0.88; 95% confidence interval [CI]: 0.75, 1.03) with curves separating as early as 24 weeks. A consistent treatment effect on cCDP12 was observed across patient subgroups and for the entire treatment duration.
• In January 2026, ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) approval for Glatiramer Acetate Injection, a treatment for Multiple Sclerosis (MS), making it the only pharmaceutical company in Taiwan to achieve this historic milestone. This achievement underscores ScinoPharm’s leadership in complex generics and highlights Taiwan’s growing recognition as a trusted contributor to the global pharmaceutical industry.
• On December 15, 2025, Sanofi provided an update on the ongoing review which stated that: (i) FDA was expecting the review to go beyond the previously communicated revised US target action date of December 28, 2025; (ii) further guidance from the FDA was expected by the end of the first quarter of 2026; and (iii) in response to an FDA request, Sanofi had submitted an expanded access protocol for tolebrutinib in nrSPMS. The announcement was based on the latest discussions with the FDA, which took place just before the update was provided.
• In August 2025, Hope Biosciences received FDA RMAT designation for its HB-adMSCs stem cell therapy for treating relapsing-remitting multiple sclerosis (RRMS).
• In June 2025, newly reported data from the Phase III OPTIMUM-LT open-label extension trial (NCT03232073) showed that treatment with Ponesimod (Vanda Pharmaceuticals) was safe and led to sustained reduction in relapses, MRI lesions, and low disability accumulation among patients with relapsing multiple sclerosis over a long-term period. At time points of up to 8.2 years, more than half of the patients included were still relapse-free.
• In May 2025, Neuralink announced that it has received the FDA’s “breakthrough” designation for its device aimed at restoring communication for individuals with severe speech impairment. The device, designed to assist patients with conditions like amyotrophic lateral sclerosis (ALS), stroke, spinal cord injury, cerebral palsy, and multiple sclerosis, represents a significant step forward in neurotechnology.
• In February 2025, Quantum BioPharma Ltd. announced that it had completed its trial entitled “A Phase I, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants.” A final safety review committee (“SRC”) meeting was held after completion of the trial. The SRC found that Lucid-21-302 “(Lucid-MS”) was well-tolerated with no safety concerns, and no serious adverse events were reported during the trial.
• In January 2025, Contineum Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications, announced that it has completed the targeted enrollment of 168 patients in its Phase II PIPE-307 VISTA trial.
• In January 2025, Century Health and Nira Medical announced a partnership to curate data from more than 3,000 patients with multiple sclerosis to advance the understanding of the disease and treatment outcomes. Based on data from Nira Medical’s network of clinics, Century Health’s AI platform will create structured datasets that will be analyzed in partnership with life sciences companies to accelerate research into MS treatment and improve patient outcomes.
• In January 2025, Pheno Therapeutics Limited announced that it had received Clinical Trial Authorization (CTA) from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its lead candidate, PTD802.
• In December 2024, the FDA granted Breakthrough Therapy Designation to Sanofi’s BTK inhibitor candidate Tolebrutinib for the treatment of adults with Nonrelapsing Secondary Progressive Multiple Sclerosis (SPMS).
• In October 2024, Immunic announced a positive outcome from the non-binding, interim futility analysis of its Phase III ENSURE program, which investigated the lead asset, nuclear receptor-related 1 (Nurr1) activator vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee (IDMC) has recommended that the trials are not futile and should continue as planned.
• In October 2024, Hope Biosciences Research Foundation (HBRF) announced positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing-remitting multiple sclerosis (MS).
• In March 2024, Immunic, Inc., announced that it had received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 16/981,122, entitled, “Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,” covering the composition-of-matter of a specific polymorph of vidofludimus calcium (IMU-838) and a related method of production of the material. The claims are expected to protect 2039, unless extended further. The patent was previously granted to the company in Australia, Canada, Indonesia, Japan, and Mexico.
• In January 2024, TG Therapeutics, Inc. announced that it has agreed with Precision BioSciences, Inc. to acquire a worldwide license to Precision’s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.

Learn more about the new multiple sclerosis drug @ Multiple Sclerosis Clinical Trials

Multiple Sclerosis Market Dynamics

The multiple sclerosis market is shaped by a complex interplay of scientific innovation, unmet medical needs, competitive drug development, and evolving healthcare policies. The multiple sclerosis market has experienced steady growth over the past decade, largely driven by an expanding patient population, earlier diagnosis, and a robust pipeline of disease-modifying therapies (DMTs). However, the market remains dynamic due to intense competition among established drugs and increasing pressure on pricing and reimbursement.

The disease-modifying therapy segment dominates the multiple sclerosis market and includes both first-line and high-efficacy treatments. Historically, injectable interferons and glatiramer acetate were the standard of care, but oral therapies such as fingolimod, dimethyl fumarate, and teriflunomide have gained substantial market share due to their convenience and efficacy. In recent years, monoclonal antibodies like natalizumab, ocrelizumab, and alemtuzumab have offered superior disease control for patients with highly active multiple sclerosis. Ocrelizumab, in particular, has reshaped the landscape by becoming the first approved treatment for primary progressive multiple sclerosis (PPMS), a previously underserved segment of the patient population.

Pipeline development is another critical factor influencing multiple sclerosis market dynamics. Numerous investigational therapies are targeting novel mechanisms, including Bruton’s tyrosine kinase (BTK) inhibitors, remyelination agents, and cell-based therapies. These candidates aim to not only halt disease progression but also promote neural repair, a major unmet need in multiple sclerosis treatment. The entry of BTK inhibitors, which offer a potentially safer and more targeted alternative to B-cell depletion therapies, could significantly alter treatment algorithms if clinical trials prove successful.

Market access and pricing pressures are increasingly shaping commercial strategies. As biosimilars of established drugs enter the market, pricing competition is intensifying, particularly in Europe and other cost-sensitive regions. Payers are demanding greater value from high-cost therapies, prompting pharmaceutical companies to invest in real-world evidence, long-term safety data, and patient-reported outcomes. Furthermore, as healthcare systems emphasize cost-effectiveness and value-based care, manufacturers must navigate complex reimbursement frameworks to maintain market share.

In summary, the multiple sclerosis market is highly dynamic and competitive, characterized by rapid innovation, shifting treatment paradigms, and evolving stakeholder expectations. Future growth will depend not only on therapeutic advancements but also on the ability of companies to demonstrate value, address unmet needs, and adapt to changing policy environments. With promising new mechanisms in development and growing attention to neurorepair and personalized medicine, the multiple sclerosis treatment landscape is poised for further transformation in the coming decade.

To know more about multiple sclerosis treatment options, visit @ Multiple Sclerosis Competitive Landscape and Therapeutics Market

Approved Multiple Sclerosis Drug Analysis

BRIUMVI: TG Therapeutics

BRIUMVI is an innovative monoclonal antibody that binds to a distinct epitope on CD20-positive B-cells. Targeting CD20 with monoclonal antibodies has become a key strategy in treating autoimmune diseases like relapsing multiple sclerosis (RMS). BRIUMVI is specifically engineered through glycoengineering to lack certain sugar molecules typically found on antibodies. This modification enhances its ability to deplete B-cells effectively at lower doses. BRIUMVI is approved for use in adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting multiple sclerosis, and active secondary progressive multiple sclerosis.

Tyruko: Sandoz

Tyruko has been designed to closely resemble the reference medicine, a well-established and highly effective anti-α4 integrin monoclonal antibody used for modifying disease progression in relapsing forms of multiple sclerosis. In the United States, Tyruko is approved as a standalone treatment for relapsing forms of MS, including clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis, as well as for treating Crohn’s disease in adults. It is the first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis.

Find out more about FDA-approved multiple sclerosis drugs @ Multiple Sclerosis Treatment Market

Multiple Sclerosis Market Drivers

1. Rising Prevalence of Multiple Sclerosis – Increasing global cases (~2.5 million worldwide) with higher incidence among women is driving demand for effective treatments.
2. Strong Pipeline of Novel Therapies – Advances in disease-modifying therapies (DMTs), biologics, and oral agents (e.g., sphingosine-1-phosphate receptor modulators, monoclonal antibodies).
3. Regulatory Approvals & Expanded Indications – Ongoing FDA/EMA approvals of innovative therapies and label expansions boost market growth.
4. Advances in Diagnostics – Improved MRI technology, biomarkers, and CSF analysis enable earlier and more accurate detection.
5. Increasing Awareness & Diagnosis Rates – Patient advocacy groups and healthcare programs promote better disease recognition and treatment uptake.
6. Personalized & Precision Medicine – AI-driven biomarker research and genetic profiling enhance targeted treatment approaches.
7. Supportive Reimbursement Policies – Coverage in developed markets encourages patient access to high-cost therapies.

Multiple Sclerosis Market Barriers

1. High Treatment Costs – Premium pricing of biologics and DMTs limits accessibility, particularly in low- and middle-income countries.
2. Adverse Effects & Safety Concerns – Long-term immunosuppressive therapies pose risks such as infections and malignancies, affecting compliance.
3. Complex Diagnosis – Lack of a definitive test and overlapping symptoms with other conditions delay timely intervention.
4. Patent Expirations & Biosimilars – Entry of generics/biosimilars threatens revenues of blockbuster drugs.
5. Regional Disparities – Limited infrastructure, specialist availability, and healthcare funding in emerging markets restrict adoption.
6. Regulatory Hurdles – Stringent approval processes and long trial durations slow market entry for new therapies.
7. Unmet Needs in Progressive Multiple Sclerosis – Current therapies are more effective for RRMS, while primary progressive Multiple Sclerosis (PPMS) and secondary progressive Multiple Sclerosis (SPMS) have fewer treatment options.

Scope of the Multiple Sclerosis Pipeline Report

• Coverage: Global
• Key Multiple Sclerosis Companies: Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen, Nucleome Therapeutics, Medsenic, TeraImmun, Autobahn Therapeutics, Guangzhou Lupeng Pharmaceutical, GlaxoSmithKline, ImCyse and others.
• Key Multiple Sclerosis Pipeline Therapies: SAR 441344, IMU-838, Orelabrutinib, Foralumab, BIIB091, JPH 034, CC-97540, PB018, Autoimmune disorder vaccines, NVG300, NT-0002, Arscimed, TI-235, LL-341070, LP-168, GSK 3888130B, IMCY-0141 and others.

Dive deep into rich insights for drugs for multiple sclerosis, visit @ Multiple Sclerosis Drugs Market

Table of Contents

1. Multiple Sclerosis Pipeline Report Introduction

2. Multiple Sclerosis Pipeline Report Executive Summary

3. Multiple Sclerosis Pipeline: Overview

4. Multiple Sclerosis Marketed Drugs

4.1. BRIUMVI: TG Therapeutics

5. Multiple Sclerosis Clinical Trial Therapeutics

6. Multiple Sclerosis Pipeline: Late-Stage Products (Pre-registration)

7. Multiple Sclerosis Pipeline: Late-Stage Products (Phase III)

7.1. IMU-838: Immunic

8. Multiple Sclerosis Pipeline: Mid-Stage Products (Phase II)

8.1. Foralumab: Tiziana Life Sciences

9. Multiple Sclerosis Pipeline: Early-Stage Products (Phase I)

9.1. JPH034: J-Pharma Co., Ltd.

10. Multiple Sclerosis Pipeline: Preclinical and Discovery Stage Products

10.1. PB018: Polpharma Biologics

11. Multiple Sclerosis Pipeline Therapeutics Assessment

12. Inactive Products in the Multiple Sclerosis Pipeline

13. Company-University Collaborations (Licensing/Partnering) Analysis

14. Unmet Needs

15. Multiple Sclerosis Market Drivers and Barriers

16. Appendix

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting